Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?

Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and metho...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	V. V. Lomivorotov [verfasserIn] S. M. Efremov [verfasserIn] E. A. Pokushalov [verfasserIn] A. B. Romanov [verfasserIn] D. N. Ponomarev [verfasserIn] A. M. Chernyavsky [verfasserIn] A. N. Shilova [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Russisch

Erschienen:	2014

Schlagwörter:	фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты

Übergeordnetes Werk:	In: Общая реаниматология - Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017, 10(2014), 5, Seite 33-43
Übergeordnetes Werk:	volume:10 ; year:2014 ; number:5 ; pages:33-43

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.15360/1813-9779-2014-5-33-43

Katalog-ID:	DOAJ000287474

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ000287474
003	DE-627
005	20230410120158.0
007	cr uuu---uuuuu
008	230225s2014 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.15360/1813-9779-2014-5-33-43 \|2 doi
035			\|a (DE-627)DOAJ000287474
035			\|a (DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a rus
050		0	\|a RC86-88.9
100	0		\|a V. V. Lomivorotov \|e verfasserin \|4 aut
245	1	0	\|a Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?
264		1	\|c 2014
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF
650		4	\|a фибрилляция предсердий
650		4	\|a искусственное кровообращение
650		4	\|a шунтирование коронарных артерий
650		4	\|a омега3 полиненасыщенные жирные кислоты
653		0	\|a Medical emergencies. Critical care. Intensive care. First aid
700	0		\|a S. M. Efremov \|e verfasserin \|4 aut
700	0		\|a E. A. Pokushalov \|e verfasserin \|4 aut
700	0		\|a A. B. Romanov \|e verfasserin \|4 aut
700	0		\|a D. N. Ponomarev \|e verfasserin \|4 aut
700	0		\|a A. M. Chernyavsky \|e verfasserin \|4 aut
700	0		\|a A. N. Shilova \|e verfasserin \|4 aut
773	0	8	\|i In \|t Общая реаниматология \|d Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017 \|g 10(2014), 5, Seite 33-43 \|w (DE-627)822100088 \|w (DE-600)2817379-X \|x 24117110 \|7 nnns
773	1	8	\|g volume:10 \|g year:2014 \|g number:5 \|g pages:33-43
856	4	0	\|u https://doi.org/10.15360/1813-9779-2014-5-33-43 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7 \|z kostenfrei
856	4	0	\|u https://www.reanimatology.com/rmt/article/view/1419 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1813-9779 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2411-7110 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 10 \|j 2014 \|e 5 \|h 33-43

Indexfelder

author_variant	v v l vvl s m e sme e a p eap a b r abr d n p dnp a m c amc a n s ans
matchkey_str	article:24117110:2014----::rteehataryhiefcsfmg3oynauaeftycdi
hierarchy_sort_str	2014
callnumber-subject-code	RC
publishDate	2014
allfields	10.15360/1813-9779-2014-5-33-43 doi (DE-627)DOAJ000287474 (DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7 DE-627 ger DE-627 rakwb eng rus RC86-88.9 V. V. Lomivorotov verfasserin aut Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients? 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты Medical emergencies. Critical care. Intensive care. First aid S. M. Efremov verfasserin aut E. A. Pokushalov verfasserin aut A. B. Romanov verfasserin aut D. N. Ponomarev verfasserin aut A. M. Chernyavsky verfasserin aut A. N. Shilova verfasserin aut In Общая реаниматология Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017 10(2014), 5, Seite 33-43 (DE-627)822100088 (DE-600)2817379-X 24117110 nnns volume:10 year:2014 number:5 pages:33-43 https://doi.org/10.15360/1813-9779-2014-5-33-43 kostenfrei https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7 kostenfrei https://www.reanimatology.com/rmt/article/view/1419 kostenfrei https://doaj.org/toc/1813-9779 Journal toc kostenfrei https://doaj.org/toc/2411-7110 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2014 5 33-43
spelling	10.15360/1813-9779-2014-5-33-43 doi (DE-627)DOAJ000287474 (DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7 DE-627 ger DE-627 rakwb eng rus RC86-88.9 V. V. Lomivorotov verfasserin aut Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients? 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты Medical emergencies. Critical care. Intensive care. First aid S. M. Efremov verfasserin aut E. A. Pokushalov verfasserin aut A. B. Romanov verfasserin aut D. N. Ponomarev verfasserin aut A. M. Chernyavsky verfasserin aut A. N. Shilova verfasserin aut In Общая реаниматология Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017 10(2014), 5, Seite 33-43 (DE-627)822100088 (DE-600)2817379-X 24117110 nnns volume:10 year:2014 number:5 pages:33-43 https://doi.org/10.15360/1813-9779-2014-5-33-43 kostenfrei https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7 kostenfrei https://www.reanimatology.com/rmt/article/view/1419 kostenfrei https://doaj.org/toc/1813-9779 Journal toc kostenfrei https://doaj.org/toc/2411-7110 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2014 5 33-43
allfields_unstemmed	10.15360/1813-9779-2014-5-33-43 doi (DE-627)DOAJ000287474 (DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7 DE-627 ger DE-627 rakwb eng rus RC86-88.9 V. V. Lomivorotov verfasserin aut Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients? 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты Medical emergencies. Critical care. Intensive care. First aid S. M. Efremov verfasserin aut E. A. Pokushalov verfasserin aut A. B. Romanov verfasserin aut D. N. Ponomarev verfasserin aut A. M. Chernyavsky verfasserin aut A. N. Shilova verfasserin aut In Общая реаниматология Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017 10(2014), 5, Seite 33-43 (DE-627)822100088 (DE-600)2817379-X 24117110 nnns volume:10 year:2014 number:5 pages:33-43 https://doi.org/10.15360/1813-9779-2014-5-33-43 kostenfrei https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7 kostenfrei https://www.reanimatology.com/rmt/article/view/1419 kostenfrei https://doaj.org/toc/1813-9779 Journal toc kostenfrei https://doaj.org/toc/2411-7110 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2014 5 33-43
allfieldsGer	10.15360/1813-9779-2014-5-33-43 doi (DE-627)DOAJ000287474 (DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7 DE-627 ger DE-627 rakwb eng rus RC86-88.9 V. V. Lomivorotov verfasserin aut Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients? 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты Medical emergencies. Critical care. Intensive care. First aid S. M. Efremov verfasserin aut E. A. Pokushalov verfasserin aut A. B. Romanov verfasserin aut D. N. Ponomarev verfasserin aut A. M. Chernyavsky verfasserin aut A. N. Shilova verfasserin aut In Общая реаниматология Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017 10(2014), 5, Seite 33-43 (DE-627)822100088 (DE-600)2817379-X 24117110 nnns volume:10 year:2014 number:5 pages:33-43 https://doi.org/10.15360/1813-9779-2014-5-33-43 kostenfrei https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7 kostenfrei https://www.reanimatology.com/rmt/article/view/1419 kostenfrei https://doaj.org/toc/1813-9779 Journal toc kostenfrei https://doaj.org/toc/2411-7110 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2014 5 33-43
allfieldsSound	10.15360/1813-9779-2014-5-33-43 doi (DE-627)DOAJ000287474 (DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7 DE-627 ger DE-627 rakwb eng rus RC86-88.9 V. V. Lomivorotov verfasserin aut Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients? 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты Medical emergencies. Critical care. Intensive care. First aid S. M. Efremov verfasserin aut E. A. Pokushalov verfasserin aut A. B. Romanov verfasserin aut D. N. Ponomarev verfasserin aut A. M. Chernyavsky verfasserin aut A. N. Shilova verfasserin aut In Общая реаниматология Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017 10(2014), 5, Seite 33-43 (DE-627)822100088 (DE-600)2817379-X 24117110 nnns volume:10 year:2014 number:5 pages:33-43 https://doi.org/10.15360/1813-9779-2014-5-33-43 kostenfrei https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7 kostenfrei https://www.reanimatology.com/rmt/article/view/1419 kostenfrei https://doaj.org/toc/1813-9779 Journal toc kostenfrei https://doaj.org/toc/2411-7110 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2014 5 33-43
language	English Russian
source	In Общая реаниматология 10(2014), 5, Seite 33-43 volume:10 year:2014 number:5 pages:33-43
sourceStr	In Общая реаниматология 10(2014), 5, Seite 33-43 volume:10 year:2014 number:5 pages:33-43
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты Medical emergencies. Critical care. Intensive care. First aid
isfreeaccess_bool	true
container_title	Общая реаниматология
authorswithroles_txt_mv	V. V. Lomivorotov @@aut@@ S. M. Efremov @@aut@@ E. A. Pokushalov @@aut@@ A. B. Romanov @@aut@@ D. N. Ponomarev @@aut@@ A. M. Chernyavsky @@aut@@ A. N. Shilova @@aut@@
publishDateDaySort_date	2014-01-01T00:00:00Z
hierarchy_top_id	822100088
id	DOAJ000287474
language_de	englisch russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ000287474</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120158.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15360/1813-9779-2014-5-33-43</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ000287474</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC86-88.9</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. V. Lomivorotov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p&lt;0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фибрилляция предсердий</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">искусственное кровообращение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">шунтирование коронарных артерий</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">омега3 полиненасыщенные жирные кислоты</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical emergencies. Critical care. Intensive care. First aid</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. M. Efremov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. A. Pokushalov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. B. Romanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. N. Ponomarev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. M. Chernyavsky</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. N. Shilova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Общая реаниматология</subfield><subfield code="d">Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017</subfield><subfield code="g">10(2014), 5, Seite 33-43</subfield><subfield code="w">(DE-627)822100088</subfield><subfield code="w">(DE-600)2817379-X</subfield><subfield code="x">24117110</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:33-43</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15360/1813-9779-2014-5-33-43</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.reanimatology.com/rmt/article/view/1419</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1813-9779</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2411-7110</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2014</subfield><subfield code="e">5</subfield><subfield code="h">33-43</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	V. V. Lomivorotov
spellingShingle	V. V. Lomivorotov misc RC86-88.9 misc фибрилляция предсердий misc искусственное кровообращение misc шунтирование коронарных артерий misc омега3 полиненасыщенные жирные кислоты misc Medical emergencies. Critical care. Intensive care. First aid Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?
authorStr	V. V. Lomivorotov
ppnlink_with_tag_str_mv	@@773@@(DE-627)822100088
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC86-88
illustrated	Not Illustrated
issn	24117110
topic_title	RC86-88.9 Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients? фибрилляция предсердий искусственное кровообращение шунтирование коронарных артерий омега3 полиненасыщенные жирные кислоты
topic	misc RC86-88.9 misc фибрилляция предсердий misc искусственное кровообращение misc шунтирование коронарных артерий misc омега3 полиненасыщенные жирные кислоты misc Medical emergencies. Critical care. Intensive care. First aid
topic_unstemmed	misc RC86-88.9 misc фибрилляция предсердий misc искусственное кровообращение misc шунтирование коронарных артерий misc омега3 полиненасыщенные жирные кислоты misc Medical emergencies. Critical care. Intensive care. First aid
topic_browse	misc RC86-88.9 misc фибрилляция предсердий misc искусственное кровообращение misc шунтирование коронарных артерий misc омега3 полиненасыщенные жирные кислоты misc Medical emergencies. Critical care. Intensive care. First aid
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Общая реаниматология
hierarchy_parent_id	822100088
hierarchy_top_title	Общая реаниматология
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)822100088 (DE-600)2817379-X
title	Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?
ctrlnum	(DE-627)DOAJ000287474 (DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7
title_full	Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?
author_sort	V. V. Lomivorotov
journal	Общая реаниматология
journalStr	Общая реаниматология
callnumber-first-code	R
lang_code	eng rus
isOA_bool	true
recordtype	marc
publishDateSort	2014
contenttype_str_mv	txt
container_start_page	33
author_browse	V. V. Lomivorotov S. M. Efremov E. A. Pokushalov A. B. Romanov D. N. Ponomarev A. M. Chernyavsky A. N. Shilova
container_volume	10
class	RC86-88.9
format_se	Elektronische Aufsätze
author-letter	V. V. Lomivorotov
doi_str_mv	10.15360/1813-9779-2014-5-33-43
author2-role	verfasserin
title_sort	are there the antiarrhythmic effects of omega3 polyunsaturated fatty acids in cardiosurgical patients?
callnumber	RC86-88.9
title_auth	Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?
abstract	Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF
abstractGer	Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF
abstract_unstemmed	Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p<0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	5
title_short	Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?
url	https://doi.org/10.15360/1813-9779-2014-5-33-43 https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7 https://www.reanimatology.com/rmt/article/view/1419 https://doaj.org/toc/1813-9779 https://doaj.org/toc/2411-7110
remote_bool	true
author2	S. M. Efremov E. A. Pokushalov A. B. Romanov D. N. Ponomarev A. M. Chernyavsky A. N. Shilova
author2Str	S. M. Efremov E. A. Pokushalov A. B. Romanov D. N. Ponomarev A. M. Chernyavsky A. N. Shilova
ppnlink	822100088
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.15360/1813-9779-2014-5-33-43
callnumber-a	RC86-88.9
up_date	2024-07-03T13:57:26.504Z
_version_	1803566497404026880
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ000287474</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230410120158.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2014 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15360/1813-9779-2014-5-33-43</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ000287474</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ7067e19005634cb7ac850bfbf176bab7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC86-88.9</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. V. Lomivorotov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective: to test the hypothesis that the perioperative use of omega3 polyunsaturated fatty acids (ω3PUFA) as intravenous infusion will reduce the risk of postoperative atrial fibrillation (POAF) in patients with coronary heart disease operated on under extracorporeal circulation.Subjects and methods. A doubleblind prospective controlled study was conducted in 39 patients who were randomized into two groups: 1) 18 patients were infused with ω3PUFA (Omegaven, Fresenius Kabi, Germany), beginning before inducing anesthesia in a dose of 200 mg/kg/day within the first 24 hours and 100 mg/kg/day on days 2 to 7 postsurgery; 2) 21 received placebo (Intralipid, Fresenius Kabi, Germany) in the equivalent dose. The primary end point was freedom from POAF during 2 months after surgery. POAF was examined using a subcutaneously implanted continuous cardiac rhythm monitoring device (Reveal XT, Medtronic, USA). Monitoring readings were taken on day 10 at 3, 6, 12, and 24 months following surgery.Results. POAF was observed in 4 (19%) patients in the placebo group and in 5 (27.8%) in the ω3PUFA group on days 10 postsurgery (p=0.88). During 2year followup, POAF was revealed in 5 (27.8%) patients in the control group and in 6 (35.3%) in the ω3PUFA group (p=0.9). The duration of POAF was associated with the risk of rehospitalizations for decompensated heart failure (regression coefficient, 0.24; standard error, 0.02; p&lt;0.0001; R2=0.74).Conclusion. The results of the study do not support the efficiency of perioperatively using ω3PUFA to prevent POAF</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фибрилляция предсердий</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">искусственное кровообращение</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">шунтирование коронарных артерий</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">омега3 полиненасыщенные жирные кислоты</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical emergencies. Critical care. Intensive care. First aid</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. M. Efremov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. A. Pokushalov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. B. Romanov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. N. Ponomarev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. M. Chernyavsky</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. N. Shilova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Общая реаниматология</subfield><subfield code="d">Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia, 2017</subfield><subfield code="g">10(2014), 5, Seite 33-43</subfield><subfield code="w">(DE-627)822100088</subfield><subfield code="w">(DE-600)2817379-X</subfield><subfield code="x">24117110</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:33-43</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15360/1813-9779-2014-5-33-43</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/7067e19005634cb7ac850bfbf176bab7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.reanimatology.com/rmt/article/view/1419</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1813-9779</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2411-7110</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2014</subfield><subfield code="e">5</subfield><subfield code="h">33-43</subfield></datafield></record></collection>
score	7.402936

Nicht das Richtige dabei?

Schreiben Sie uns!

Are There the Antiarrhythmic Effects of Omega3 Polyunsaturated Fatty Acids in Cardiosurgical Patients?

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?